Thyroid Carcinoma NGS Panel with Fusion

Abbrev Code:THYROID CA   
Order Code:LAB8288Order Name:Thyroid Carcinoma NGS Panel with Fusion
Methodology:Next Generation Sequencing
CPT Codes: 81455 x1, G0452 x1
Test Includes:See Beaker NGS Oncology Panel Gene List for a comprehensive list of genes contained within each available panel.
Turnaround Time:Performed Mon-Fri; results are reported within 10 days.

Collection Instructions

Specimen:Fixed tissue slides; paraffin block
Optimal Volume:9 unstained slides (10 microns thick) and 1 H&E slide (10 microns thick) fixed tissue
Minimum\Peds Volume:5 unstained slides (10 microns thick) and 1 H&E slide (10 microns thick) fixed tissue
Container:Plastic leakproof container, sterile
Causes for Rejection:Fixative other than formalin, decalcified tissue

Processing and Shipping

Specimen Processing:Do not process. Store at room temperature.
Shipping Instructions:Ship at room temperature. Do not refrigerate or freeze
Test Performed at or Referral Lab UM Molecular Diagnostics (M)  (UMMC East Bank)


Reference Range:By interpretive report.
Use:Next Generation Sequencing of DNA to assess for somatic mutations in the indicated gene panel. NGS Fusion panel is included for detection of translocations (including NTRK).

Thyroid cancer counts towards 5% of cancer diagnosed in women in the US. 30% often reoccur locally and 15% develop distant metastatic disease. BRAF V600E is the most common gene (40-60%) mutated in thyroid cancer along with RAS (30%). Some less common but still prevalent include RET, TP53, ALK, TERT, and PTEN. Activating mutation in the PI3K/AKT pathway involves PIK3CA, AKT, and ERB2 are identified as well. Although surgery and radioactive iodine do provide initial therapies, molecular profiling can provide better tumor assessment and targeted therapies for more progressive and metastatic advanced disease

Click HERE to Report test errors or omissions.
*If no email program is associated with this computer, please contact:
[email protected] for TestID: 7029"